This inventor holds 44 USPTO granted patents and 34 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in RNA Interference. Top assignees: Arrowhead Pharmaceuticals, Inc., Arrowhead Madison, Inc., Empirico Inc.. Active years: 2006-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
19 out of 102 
10 out of 19 
9 out of 11 
Years Active: 2006-2026
Areas of Expertise:
Title: Innovative Contributions of David L Lewis in Gene Expression Research
Introduction
David L Lewis, based in Madison, WI, is a notable inventor with an impressive portfolio of 40 patents. His work primarily focuses on gene expression and the innovative methods surrounding it, making significant strides in the field of biotechnology and pharmaceutical development.
Latest Patents
Among his latest patents are "Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin." This invention relates to RNA interference triggers designed to inhibit the expression of the AAT gene, utilizing a mechanism of RNA interference. The invention also includes a pharmaceutical composition that contains the AAT RNAi trigger alongside an excipient that enhances the delivery of this trigger to liver cells in vivo. The efficient delivery mechanism aids in the treatment of alpha-1 antitrypsin deficiency and related diseases.
Another significant patent by Lewis involves "Compositions and methods for inhibiting gene expression of Hif2alpha." This patent describes RNA interference (RNAi) triggers and RNAi trigger conjugates aimed at inhibiting the expression of the Hif2α (EPAS1) gene. The invention also outlines pharmaceutical compositions containing Hif2α RNAi triggers, which may be used in conjunction with additional therapeutics. The targeted delivery of these Hif2α RNAi triggers to tumor cells in vivo holds promise for cancer treatment.
Career Highlights
David L Lewis has contributed immensely to the field through his work with prominent companies, including Arrowhead Pharmaceuticals, Inc. and Arrowhead Madison, Inc. His innovative approaches have positioned him as a valuable asset in the biotechnology sector, paving the way for advancements in genetic therapies.
Collaborations
Throughout his career, Lewis has collaborated with esteemed colleagues, including David B Rozema and Darren H Wakefield. These partnerships have fostered a conducive environment for innovation, leading to the development of groundbreaking therapeutic solutions.
Conclusion
David L Lewis continues to make significant contributions to the realm of gene expression and targeted therapies. His extensive patent portfolio reflects his commitment to advancing biotechnological innovations, solidifying his role as a key inventor in addressing critical health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile